Orion Portfolio Solutions LLC Sells 3,073 Shares of Integer Holdings Co. (NYSE:ITGR)

Orion Portfolio Solutions LLC decreased its position in shares of Integer Holdings Co. (NYSE:ITGR) by 25.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,227 shares of the medical equipment provider’s stock after selling 3,073 shares during the quarter. Orion Portfolio Solutions LLC’s holdings in Integer were worth $1,223,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in ITGR. Mather Group LLC. grew its holdings in Integer by 304.3% during the 4th quarter. Mather Group LLC. now owns 190 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 143 shares in the last quarter. Lee Danner & Bass Inc. bought a new position in shares of Integer during the fourth quarter valued at approximately $27,000. R Squared Ltd purchased a new position in Integer during the fourth quarter valued at approximately $44,000. Versant Capital Management Inc raised its stake in Integer by 98.4% in the fourth quarter. Versant Capital Management Inc now owns 369 shares of the medical equipment provider’s stock worth $49,000 after buying an additional 183 shares in the last quarter. Finally, Principal Securities Inc. lifted its holdings in Integer by 31.2% during the fourth quarter. Principal Securities Inc. now owns 639 shares of the medical equipment provider’s stock worth $85,000 after buying an additional 152 shares during the period. Hedge funds and other institutional investors own 99.29% of the company’s stock.

Integer Trading Down 1.9 %

NYSE:ITGR opened at $113.87 on Friday. The company has a market capitalization of $3.83 billion, a P/E ratio of 33.89, a PEG ratio of 1.72 and a beta of 1.24. The company has a current ratio of 2.95, a quick ratio of 2.09 and a debt-to-equity ratio of 0.62. Integer Holdings Co. has a 12 month low of $107.11 and a 12 month high of $146.36. The firm has a fifty day simple moving average of $128.00 and a 200-day simple moving average of $131.69.

Integer (NYSE:ITGR) last issued its quarterly earnings results on Thursday, February 20th. The medical equipment provider reported $1.43 EPS for the quarter, missing analysts’ consensus estimates of $1.46 by ($0.03). Integer had a return on equity of 11.65% and a net margin of 6.92%. The firm had revenue of $449.50 million for the quarter, compared to analyst estimates of $446.28 million. On average, equities research analysts anticipate that Integer Holdings Co. will post 6.01 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Truist Financial boosted their price target on Integer from $147.00 to $163.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. KeyCorp increased their price target on shares of Integer from $144.00 to $154.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. Citigroup lifted their price objective on shares of Integer from $130.00 to $145.00 and gave the stock a “neutral” rating in a research report on Wednesday, December 11th. Raymond James started coverage on shares of Integer in a research report on Friday, March 28th. They set an “outperform” rating and a $145.00 target price for the company. Finally, Oppenheimer downgraded shares of Integer from an “outperform” rating to a “market perform” rating in a research note on Friday, February 21st. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $148.56.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.